Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Acrux ( (AU:ACR) ) just unveiled an update.
Acrux Limited has received a $3.04 million R&D Tax Incentive rebate from the Australian Tax Office for FY25, which has allowed them to repay their short-term funding facility from Radium Capital. This rebate underscores Acrux’s commitment to investing in research and development in Australia, aligning with the government’s vision of fostering a future driven by Australian science.
More about Acrux
Acrux is a specialty pharmaceutical company known for its expertise in developing and commercializing topically applied pharmaceutical products. With 25 years of experience, Acrux has successfully marketed several products globally, particularly focusing on the United States.
Average Trading Volume: 508,257
Technical Sentiment Signal: Sell
Current Market Cap: A$6.14M
See more data about ACR stock on TipRanks’ Stock Analysis page.